Has Cel-Sci (CVM) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Cel-Sci (CVM), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Cel-Sci is a member of the Medical sector. This group includes 757 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CVM is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for CVM's full-year earnings has moved 8.65% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, CVM has gained about 76.74% so far this year. At the same time, Medical stocks have gained an average of 6.34%. As we can see, Cel-Sci is performing better than its sector in the calendar year.
Looking more specifically, CVM belongs to the Medical - Biomedical and Genetics industry, a group that includes 280 individual stocks and currently sits at #95 in the Zacks Industry Rank. On average, stocks in this group have lost 1.42% this year, meaning that CVM is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track CVM. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cel-Sci Corporation (CVM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
